Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04087629 · ClinicalTrials.gov registry record · NA
StrataCTX® as a Steroid Sparing Device
A NA study of CTCL, sponsored by Columbia University.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT04087629 is a NA study of CTCL that is actively recruiting participants, run by Columbia University. The registered enrollment target is 70 participants, above the 59-participant average among 4 other CTCL trials with a reported enrollment target (19% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04087629, a NA study of CTCL, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatment for CTCL, or chemotherapy/immunotherapy for solid/hematologic malignancies. Subjects will have CTCL and are being treated with topical steroids, or being treated with chemotherapy/immunotherapy for another condition and have had cutaneous reactions that have warranted initiation of topical steroids.
Conditions Studied
Interventions
- DEVICE StrataCTX® gel
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2021-07-07 |
| Est. Completion | 2026-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04087629
The ClinicalTrials.gov registry entry for NCT04087629 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 59-participant average among 4 other CTCL trials with a reported enrollment target (19% higher). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with CTCL appearing as the primary indexed condition, and to 1 intervention - of which StrataCTX® gel is the first listed.
NCT04087629 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04087629 about?
NCT04087629 is a clinical study titled "StrataCTX® as a Steroid Sparing Device". The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatm...
What is the current status of trial NCT04087629?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2021-07-07. Estimated completion is 2026-08.
What conditions does trial NCT04087629 study?
This clinical trial studies the following conditions: CTCL.
What interventions are being tested in trial NCT04087629?
The interventions under investigation include: StrataCTX® gel (DEVICE).
Who is sponsoring clinical trial NCT04087629?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04087629 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CTCL
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
RECRUITING · Phase 3
-
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
RECRUITING · Phase 2
-
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
ACTIVE NOT RECRUITING · Phase 1
-
A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.